OBJECTIVE: To design and evaluate new pharmacogenomic (PGx) clinical decision support (CDS) alerts, built to adhere to PGx CDS design principles developed through socio-technical approaches.
well educated on the benefits of PGx, or on methods to implement it effectively in treating patients. [8, 9] Additionally, the rapidly changing field of genomics makes it hard for any one individual to keep up with the shifting science and associated clinical recommendations. Clinical decision support (CDS) systems have the ability to close this gap by conveying useful PGx knowledge to prescribers at the point of care, [10] without requiring time-consuming continuing medical education that most clinicians find burdensome. [11] To-date, PGx CDS systems have shown mixed results in their level of effectiveness and clinician-acceptance. The wide variation in the design and outcomes of first-generation PGx CDS systems confirms that there are no current, widely accepted best practices for how to design alerts to be as effective and useful for clinicians as possible. We previously examined the alerts implemented at Northwestern Medicine (NM) and found generally low acceptance and compliance rates with PGx recommendations. [12] Other sites in the Electronic Medical Records and Genomics (eMERGE) Network showed a wide range of effectiveness and design choices, though with some emerging consensus around the use of post-genetic test, interruptive alerts based on Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations integrated into the EHR. [13] Non-eMERGE sites have taken a variety of different approaches to their implementations, as well. The Genomic Prescribing System at the University of Chicago is a standalone system that has been shown to affect prescriber decision-making using "traffic light" recommendations, [14, 15] while St. Jude's and the NIH Clinical Center developed interruptive alerts, with substantially different clinician compliance rates. [16, 17] Although a number of sites have opted for interruptive alerts, there remains wide variation in the design and function of those alerts. For PGx CDS to reach its potential, we must establish best practices and guidelines for alert design to ensure that knowledge is conveyed to prescribers in a meaningful way that will actually improve patient care and outcomes. Non-PGx CDS has a broad base of research to draw upon, [18] [19] [20] [21] but low levels of provider education in PGx raises the possibility that information needs for PGx CDS may be substantially different from areas where clinicians have been extensively trained, such as drug-drug and drug-allergy interactions.
Socio-technical design methods have the potential to help identify clinician needs and best practices for PGx CDS. These methods emphasize inclusion of the user in the design process in order to best evaluate actual needs. They also utilize repeated evaluation of, and iteration upon, designs. [22] [23] [24] In prior work, we applied these techniques and identified several potential principles for PGx CDS alert design. [25] In this study, we build upon that work and propose and evaluate a series of updated PGx CDS designs based on those principles, in comparison to the previous committee-developed designs at NM. We suggest that the designs based on socio-technically developed principles will lead to better response by clinicians on a variety of metrics. If effective, then these principles can be adopted more broadly in the field to ensure PGx CDS reaches its potential for bringing precision medicine to fruition.
Objective
This study sought to compare clinician response to PGx CDS (including action taken, time taken, confidence, and overall satisfaction) for alert designs built with two different approaches. The first approach was a set of committee-developed designs, established through informal user input and previously implemented at Northwestern Medicine. The second approach was a set of revised designs, based on the results of formal socio-technical design work described in a previous paper. [25] 
Materials and Methods

Overview
Participants in this study took part in a user test consisting of a series of 24 interactive simulations based on fictionalized, but realistic, clinical scenarios involving PGx CDS and were asked to engage in a think-aloud protocol. Simulations were designed to mimic familiar EHR workflows. Twelve scenarios used existing PGx CDS alert designs, developed in earlier phases of NU's eMERGE-PGx project ("original designs"). Twelve scenarios used new PGx CDS alert designs, developed via socio-technical design methods ("new designs"). After each scenario, participants were asked to rate their confidence in their actions and explain their reasoning if they chose to ignore an alert. After completing all 24 scenarios, participants completed a short questionnaire assessing their preferences between the different designs. All testing sessions included screen and audio recording for later analysis. The Northwestern IRB approved all aspects of this study.
Study Development
Alert Development
We first developed a series of new PGx CDS design prototypes. These designs were based on the results of prior research and on general human-computer interaction and user interface design principles applicable to clinical decision support. [18] [19] [20] [21] 25 ] New design 6 prototypes were initially developed by TMH and then iteratively refined based on group feedback (JBS, LVR, TAM). The design principles established from prior research, and how they were addressed in the new designs, are detailed in Table 1 . Some of these principles and approaches are consistent with those used in traditional CDS, but several are unique to PGx CDS, including the use of stronger wording in recommendations, the use of phenotypes abstracted from the underlying genotype data, and emphasis on adaptability for learning effects. • Some alerts appear in summary form that can be expanded for more details • All alerts are designed to be easily skimmed by those with more experience, with details and links for those that need more information [a] Design principles derived from previous work. [25] 
Figure 1 -PGx CDS Design Comparison
Original Design:
New Design, Brief:
The new alerts were developed for the same drug-gene interactions (DGIs) and clinical scenarios as in previous eMERGE-PGx work, but with updated UIs and workflows. Table 2 details each of the eleven distinct alerts that were developed. 
Scenario Development
A total of 24 different clinical scenarios were developed, using fictional patient information. Each scenario was based on common clinical indications for use of clopidogrel, simvastatin, and warfarin. One scenario was developed for each of the eleven new alert designs, with an additional scenario for warfarin. The additional scenario for warfarin would allow participants multiple exposures to warfarin alerts under different clinical conditions. This resulted in a total of twelve unique scenarios. Analogous scenarios were then developed and paired with the original designs, resulting in a total of 24 testing scenarios. Patient demographics and scenario wording were altered slightly to avoid clear repetition and immediate recognition by participants.
The fictitious patient information for each scenario was based on typical patient demographics for users of these particular medications. Scenarios were evenly split between male and female. Height, weight, and smoking status were based on national averages. Ages were chosen to be clinically reasonable according to national averages for the clinical indication and medication relevant to that scenario.
In addition to patient demographics, each scenario had an associated initial medication (clopidogrel/simvastatin/warfarin), a recommended alternative (prasugrel/atorvastatin/reduced warfarin dose), and an expected action (accept alert/dismiss alert).
All scenarios (including the expected action) were independently reviewed for clinical validity by two MDs before being presented to participants (JBS and one non-author).
Reviewers concurred and neither recommended any changes to the scenarios, as written.
Simulation Development
Interactive simulations were developed as a web application, using HTML, JavaScript, and CSS. The user interface was created in an image manipulation program and was based on a series of screenshots from NM's actual EHR implementation (Epic Systems Corporation, Verona, WI). All simulated alerts were interactive, with functional hyperlinks, educational materials, and buttons. However, most workflow aspects outside of the alerts were removed or abbreviated for simplicity. In particular, for scenarios using the original designs, the workflow for ordering after-visit summary materials and for updating a medication were greatly shortened. Figure 2 shows an example of a simulated workflow using one of the new alert designs.
Figure 2 -Example Simulation
Screenshot of a simulated EHR sequence in a web application built for user testing of new pharmacogenomic clinical decision support alert designs. Here, the user has attempted to order 75mg of clopidogrel when the patient is a poor metabolizer.
Study Execution
Study participants were recruited from NM's General Internal Medicine (GIM) and
Cardiology departments. Participants were approached via e-mail, based on their participation in previous eMERGE studies or through snowball sampling through referrals from other participants. All participants were compensated with a $100 gift card for their participation.
All testing sessions were conducted via think-aloud protocol, either in person or via virtual conference, with the first author present. Participants were encouraged to share their thought processes while executing each of the simulations in order to benefit later review and analysis. Participants were permitted to ask questions about the simulations as they went through their testing session. All sessions were recorded via a virtual conferencing application and were later exported to standalone video. In-person participants were provided a mouse and laptop with the testing application pre-loaded and configured. Virtual conference participants used their own PCs and were provided a copy of the web application ahead of time to run locally.
To mitigate potential learning effects, participants were evenly divided into "Original First" and "New First" conditions. The scenarios and associated simulations were identical for all participants, but the simulation order varied, as follows: The Original First group saw the twelve original designs first, followed by the twelve new designs. The New First group saw the twelve new designs first, followed by the twelve original designs. The order of the scenarios within each "bundle" was randomized for each participant. There was no "washout period" between the bundles of scenarios, as the participants proceeded immediately from the first group to the second group. Participants were assigned to their respective groups on an alternating basis.
The overall study flow was identical for each participant, outside of the simulation order.
Each session started with the participant consenting to the study, followed by five verbal demographics questions assessing their experience, education, and familiarity and comfort with PGx. Participants were then provided with the web application for user testing. The web application began with an instruction screen, from which participants clicked a link to begin the study. Participants then saw a Scenario Description screen with a short paragraph detailing the clinical scenario and a link to begin the simulation. They would then execute the simulation and complete it by clicking a "Sign Visit" or "Sign Orders" button. This was followed by a short screen asking them to rate their confidence in their choice on a 0-10 Likert scale and, if they ignored or dismissed an alert, asking them to verbally explain their rationale to the interviewer.
Participants would then click a link to view the next Scenario Description screen and repeated this process for all 24 simulations. After the final post-simulation screen, participants were taken to a wrap-up questionnaire where they answered five Likert-scale questions to assess their preferences between the original and new designs, and three open-ended questions to determine any recommendations they may have for further improving the alert designs. All questions asked for opinions on "Type 1" or "Type 2" alerts. Type 1 and Type 2 were alternated for each participant, depending on whether they saw the original designs or new designs first.
Analysis
Analysis was divided into four key metrics: Response, Satisfaction, Speed, and Confidence, each with a different means of assessment.
In concordance with prior work by this research group, [12, 13] Response was defined in two ways: Alert Response and Clinical Response. Alert Response was the response to the alert itself in the simulated EHR and could be either Accept (i.e., the user clicked the "Accept" button on the alert) or Ignore (i.e., the user clicked the "Dismiss" button on the alert or proceeded with no interaction on the alert). Clinical Response was the clinical action taken and could be either Speed was determined by the number seconds elapsed from the time the participant clicked the "Begin Simulation" link for each scenario to the time they clicked the "Sign Visit" or "Sign Orders" button to complete the scenario. This value was determined through a frame-byframe examination of the session recordings by the first author.
Confidence was determined by a combination of the individual "0-10" confidence scores participants provided at the end of each scenario, as well as an overall confidence question asked during the wrap-up questionnaire phase.
Results
Basic Demographics
Twelve clinicians agreed to take part in this study, including eleven MDs and one PA.
Six participants were board certified in internal medicine only and six were board certified in cardiology-related specialties. Participants had an average of 18 years of experience and spent 13.5 hours per week seeing patients. When asked about their comfort with genetics and pharmacogenetics, four participants expressed low comfort levels, six expressed fair or moderate comfort levels, and two expressed high comfort levels. Participants generally reported infrequent use of genetic data in their practice, with only one participant saying they used genetic data often. This is consistent with responses seen in previous publications. [12, 13] A technical issue compromised the measurements for one participant during the study. Figure 3 shows how each participant answered each of the five questions and Figure 4 shows the preference distributions for each question. All five individual questions showed preference for the new designs, via one-sample Wilcoxon Signed Rank analysis, both without and with Bonferroni correction for multiple tests. Results on the individual questions are summarized in Table 6 .
Figure 3 -PGx CDS Version Preferences
Preferences expressed by twelve participants comparing Original and New pharmacogenomic clinical decision support alert designs. 
Learning Curve
Most of the difference in task time comes from the earliest tasks in each sequence, indicating a likely learning curve for the original designs. Participants who saw the original designs first were much slower at earlier simulations than they were at later ones. Conversely, participants who saw the new alert designs first showed similar task times from start to finish. 
Original Designs New Designs
Because of the randomized nature of the simulation order, direct one-to-one comparisons for each task was not feasible. So, to evaluate the possible learning curve, we examined the mean task times in three separate buckets: First Four, Second Four, and Third Four. Table 6 shows that there is a significant time difference in the first four tasks for the Original First group over the New First group. The difference in mean times for the Second Four and Third Four buckets is much smaller and not statistically significant. Furthermore, there was no difference in average task time between the original designs and new designs when seen second, at 42 and 39 seconds, respectively (two sample, one-tail t-test; H0: µ1≤µ2; p=0.34). Taken all together, this is evidence that the time differences are due to a substantial learning curve with the original designs that is not present with the new designs, and that the learning curve exists within the first four exposures. 
Discussion
This study successfully demonstrates that socio-technical techniques can improve PGx CDS alert designs. Participants in this study showed greater satisfaction, lower task times, greater confidence, and improved concordance of actions when interacting with revised alerts, with no evidence of any deleterious effects on accuracy.
Though we were unable to demonstrate that the new designs lead to greater accuracy, we did find a positive trend in Clinical Response that may be significant with greater statistical power. Additionally, clinician behavior was more concordant between Alert Response and Clinical Response. This is likely due to a workflow change in the new designs. The new designs automatically update the user's order with the recommended medication when they accept an alert (a reflection of the "Be Specific and Actionable" design principle), while the original designs require users to manually update their order. This manual process introduces the opportunity for divergence between the Alert Response and Clinical Response actions, which could cause confusion for users and complications for system evaluators.
The increase in confidence we observed from individual scenario scores is further supported by the results from the end-of-study questionnaire, where participants reported being more confident overall with the new designs. However, that result was the weakest of the five end-of-study questions, which aligns with the relatively modest increase in confidence that we found.
The Alert Response and Clinical Response rates in this study were significantly higher than rates found in live clinical data in a previous study at NM, where clinicians accepted the original-style alerts 42.5% of the time and ordered an alternative medication 22.5% of the time. [12] These rates are substantially lower than in this study, where clinicians accepted the original designs 69.5% of the time and ordered an alternative medication 66.1% of the time.
There are several possible reasons for this result, including that the simulations in this study were not time-bound, so participants were able to take the time they needed to review alerts and make a choice in which they felt confident. In live clinical settings, users may be reluctant to take the time to review the unfamiliar alerts and change their behavior, particularly given the substantial learning curve we found for the original designs. We do not see any reason to believe this would bias one condition over the other in our study. Also, given the reduced learning curve and task times with the new designs, clinicians may be even more likely to follow the new designs in a time-constrained setting, leaving our overall conclusions unchanged. Additionally, the Hawthorne Effect [26] may be present in this study, as participants were fully aware that they were being observed. But again, we see no reason to believe this would bias one condition over the other, and therefore do not believe our conclusions are affected.
The present study adds to a small but growing base of literature examining the effectiveness of PGx CDS, of which some previous studies have also utilized socio-technical approaches. Our results dovetail with previous studies from the University of Washington.
Devine, et al. found that physicians expressed a desire for PGx CDS to "provide succinct, relevant guidelines and dosing recommendations of phenotypic information from credible and trustworthy sources; any more information was overwhelming." [27] Here, we find that such designs do, in fact, improve physician satisfaction with PGx CDS. Subsequently, Overby et al.
performed an evaluation of a PGx CDS prototype and found that PGx CDS lowered physician confidence in their decision-making, but significantly altered their dosing decisions. [28] Our results contradict those findings, as we found an increase in confidence but little change in decision making. It is likely that differences in design, workflow, or physician characteristics contributed to these divergent results, which emphasizes the need for further research to fully understand how such factors affect clinician response to PGx CDS. Our findings are congruent with their conclusion that effective PGx CDS is "likely to be realized through continued focus on content, content delivery, and tailoring to physician characteristics." [28] Other The simulated nature of the study does not perfectly mimic an actual clinical setting with all the time pressures, potential distractions, and emotional involvement of an actual patient that such a setting would entail. We instructed clinicians to work quickly and act as they would with a real patient, but the extent to which they were able to accomplish this is unclear.
The times collected for the speed metric are not likely to reflect actual clinical times because of the think-aloud protocol the study employed. However, there is little reason to believe that the time required to think aloud would change the conclusion that the new designs are faster for clinicians. Several articles in the literature discuss how think-aloud protocols affect task times and accuracy, but we were unable to find any case where such protocols would bias one study condition over another when both conditions include a think-aloud component. [31, 32] Additionally, as described in the Materials and Methods section, the simulations for the original designs were significantly shortened to reduce complexity in the web application. The simulations for the new designs were not shortened, a fact that further strengthens our conclusions. Moreover, most of the time difference was due to a large learning curve with the original designs, where early exposures took clinicians much longer to respond. Given the low frequency of interaction that clinicians have with PGx CDS in real-world clinical settings, [12] we expect that the earlier, slower times in this study more closely reflect real-world interactions.
With these limitations in mind, we conclude that the new designs are faster, with a reduced learning curve, but we make no claim as to the magnitude of the change in real-world task time.
This study is further limited by its sampling methods. Participants were not randomly sampled, but instead were clinicians that had worked with PGx before, had participated in a prior eMERGE-PGx study, or who showed interest in the project via professional networking.
Furthermore, participation was limited to GIM and Cardiology departments at a single large, academic medical center. All of these factors make it possible that participants were more informed about PGx in general, and as such, the results may not generalize to other clinical populations. However, the low to moderate comfort level with, and infrequent use of, genetics that participants reported may indeed reflect the attitudes of a typical clinician.
Future work can build upon this study in a number of ways. We recorded the user testing sessions and asked participants to think aloud during their simulations, which could provide additional fruitful data. The final wrap-up survey also asked open-ended questions that encouraged participants to suggest improvements to the new designs. These qualitative analyses are left for a future study. Anecdotally, there are minor tweaks that could lead to even greater satisfaction with the new designs -such as a "Preview" link for the patient educational materials and renaming the "Accept" button to "Order [alternative]" to further clarify the workflow.
Most importantly, this successful pilot demonstration should be followed up with a realworld implementation and evaluation. To the extent that it is technically feasible, the alert designs in this study should be translated to live alerts in an active EHR and subjected to similar evaluations as our previous studies of the original alert designs. [12] Iteration and continual improvement are critical aspects of socio-technical design.
Conclusion
This study validates the PGx CDS design principles we previously proposed and provides strong evidence that socio-technical design approaches lead to better results with PGx CDS than design by committee. The updated designs tested in this study led to more satisfied, faster, and more confident clinicians who were at least as accurate in their decision making as with prior, committee-developed designs. These results support previous findings that, for PGx, clinicians prefer brief, actionable alerts that contain specific recommendations based on interpreted phenotypes. As a next step, these alert designs should be implemented in a live clinical setting to confirm that they lead to similar real-world results.
